To address this possibility, we compared the transcriptomes of PRAD organoids treated with vehicle control (DMSO), single inhibitors (TEADi, NOTCHi or ARi), doublet combinations (TEADi /NOTCHi, TEADi/ARi, NOTCHi/ARi) and COMBO in a time course experiment. This evidence concerns the gene ARIH1 and prostate adenocarcinoma.